Multispecific antibodies, multispecifically activatable antibodies, and methods for using them.
Multispecific antibodies with masking moieties address the limitations of monoclonal antibodies by selectively targeting multiple disease-related antigens and activating immune cells at disease sites, enhancing therapeutic efficacy and reducing side effects.
JP7873695B2Active Publication Date: 2026-06-12CYTOMX THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- CYTOMX THERAPEUTICS INC
- Filing Date
- 2024-03-28
- Publication Date
- 2026-06-12
AI Technical Summary
Technical Problem
Monoclonal antibodies often fail to effectively target multiple disease-related targets due to limited therapeutic efficacy and broad target expression, leading to toxicity and rapid clearance from circulation.
Method used
Development of multispecific antibodies and activatable antibodies with masking moieties that reduce antigen-binding in normal tissues, allowing targeted activation and enhanced selectivity at disease sites, mobilizing immune effector cells like T cells and NK cells.
Benefits of technology
Enhances therapeutic efficacy by selectively targeting multiple antigens or epitopes while minimizing side effects, activating immune cells at disease sites, and reducing autoreactive responses.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007873695000096 
Figure 0007873695000097 
Figure 0007873695000098
Abstract
To provide multispecific antibodies and multispecific activatable antibodies that specifically bind to multiple different antigens or epitopes, and methods of making and using these multispecific antibodies and / or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic applications.SOLUTION: The present invention provides multispecific activatable antibodies that are multispecific antibodies that include at least one masking moiety (MM) linked to at least one antigen- or epitope-binding domain of the multispecific antibody such that coupling of the MM reduces the ability of the antigen- or epitope-binding domain to bind its target.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art